Infigratinib
- Generic Name
- Infigratinib
- Brand Names
- Truseltiq
- Drug Type
- Small Molecule
- Chemical Formula
- C26H31Cl2N7O3
- CAS Number
- 872511-34-7
- Unique Ingredient Identifier
- A4055ME1VK
- Background
Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor. By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth. Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy. Infi...
- Indication
Infigratinib is indicated for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test.
- Associated Conditions
- Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas
- Associated Therapies
- -
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- LianBio LLC
- Target Recruit Count
- 6
- Registration Number
- NCT06206278
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳The Second Hospital Lanzhou University, Lanzhou, Gansu, China
Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
- Conditions
- Interventions
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05510427
Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations
- Conditions
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Helsinn Healthcare SA
- Registration Number
- NCT05222165
- Locations
- 🇨🇦
McMaster Children's Hospital (MCH), Hamilton, Ontario, Canada
🇨🇦University of Alberta - Stollery Children's Hospital (SCH), Edmonton, Alberta, Canada
🇺🇸Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States
Extension Study of Infigratinib in Children with Achondroplasia (ACH)
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT05145010
- Locations
- 🇬🇧
University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom
🇺🇸USCF Benioff Children's Hospital, Oakland, Oakland, California, United States
🇺🇸Nemours Alfred I. Dupont Hospital for Children, Wilmington, Delaware, United States
Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations
- Conditions
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- LianBio LLC
- Target Recruit Count
- 80
- Registration Number
- NCT05019794
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
Phase I BLASST-3 Trial
- Conditions
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Guru P. Sonpavde
- Registration Number
- NCT04972253
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Jennifer Lee Caswell-Jin
- Target Recruit Count
- 4
- Registration Number
- NCT04504331
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Infigratinib in Recurrent High-Grade Glioma Patients
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Nader Sanai
- Target Recruit Count
- 7
- Registration Number
- NCT04424966
- Locations
- 🇺🇸
Chandler Regional Medical Center, Chandler, Arizona, United States
🇺🇸St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸HonorHealth Scottsdale Osborn Medical Center, Scottsdale, Arizona, United States
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Sameek Roychowdhury
- Target Recruit Count
- 17
- Registration Number
- NCT04233567
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer
- First Posted Date
- 2020-01-14
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT04228042
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.